Feasibility of mobile device-based patient-reported outcomes in real-world clinical settings for non-small cell lung cancer
Precision and Future Medicine · 30.06.2026 · 10 (2) · 90-101
DOI: 10.23838/pfm.2026.00100 ↗Kurz gefasst
Fachartikel in der Zeitschrift Precision and Future Medicine, erschienen am 30.06.2026. Verfasst von Changgon Kim und 9 weiteren Autor:innen. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Evidence-based Healthcare Collaborating Agency.
Abstract (Originalsprache)
Purpose
This study evaluated the feasibility and clinical utility of a mobile application-based electronic patient-reported outcome (ePRO) system for longitudinal symptom monitoring in patients with lung cancer receiving systemic therapy.
Methods
We developed a mobile application-based ePRO platform for patients with lung cancer receiving chemotherapy and/or immunotherapy in South Korea. Twenty-one treatment- related symptoms were selected from regulatory drug labeling and mapped to Patient- Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) items. Patients reported symptoms every 3 days or as needed, while clinicians reviewed the summarized data via a web-based interface. The adherence, usability, and concordance between patient- and clinician-reported adverse events (AEs) were assessed.
Results
A total of 26 patients used the application, generating 570 symptom reports over a mean follow-up duration of 70.3±64.5 days. The mean adherence rate was 81.9%±21.5%. The most frequently reported symptoms were fatigue (67.7%), shortness of breath (60.1%), decreased appetite (59.9%), insomnia (57.6%), and pain (53.8%), with decreased appetite, fatigue, and shortness of breath being the most common grade ≥2 symptoms. Symptom patterns varied according to the treatment regimen and were consistent with known toxicity profiles. Clinician-documented AEs were primarily limited to laboratory abnormalities, whereas ePRO captured a broader range of subjective symptoms. Longitudinal analysis revealed sustained weekly reporting, regimen-specific temporal symptom trajectories, and higher symptom severity in unscheduled reports than in scheduled reports.
Conclusion
Mobile application-based longitudinal ePRO monitoring was feasible, well accepted, and clinically informative for lung cancer care. These findings support further evaluation of mobile ePRO systems in routine practice.
Förderung
- National Evidence-based Healthcare Collaborating Agency
Zitieren
APA
Kim, C., Kim, J., Nam, B., Kim, J., Jung, H. A., Sun, J., Lee, S., Ahn, J. S., Ahn, M., & Park, S. (2026). Feasibility of mobile device-based patient-reported outcomes in real-world clinical settings for non-small cell lung cancer. Precision and Future Medicine, 10(2), 90-101. https://doi.org/10.23838/pfm.2026.00100
Vancouver
Kim C, Kim J, Nam B, Kim J, Jung HA, Sun J, et al. Feasibility of mobile device-based patient-reported outcomes in real-world clinical settings for non-small cell lung cancer. Precision and Future Medicine. 2026;10(2):90-101. doi:10.23838/pfm.2026.00100
BibTeX
@article{Kim2026,
author = {Kim, Changgon and Kim, Jinyong and Nam, Byung-Ho and Kim, Junkyu and Jung, Hyun Ae and Sun, Jong-Mu and Lee, Se-Hoon and Ahn, Jin Seok and Ahn, Myung-Ju and Park, Sehhoon},
title = {Feasibility of mobile device-based patient-reported outcomes in real-world clinical settings for non-small cell lung cancer},
journal = {Precision and Future Medicine},
year = {2026},
volume = {10},
number = {2},
pages = {90--101},
doi = {10.23838/pfm.2026.00100}
}
EUVIMED